Mustang Bio, Inc.
MBIOHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. Valued at $2.8M, MBIO is a micro-cap name in its sector. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Market Cap
$2.8M
Beta
2.09
P/E (TTM)
—
P/E (Fwd)
-1.06
EPS (TTM)
$-0.44
EPS (Fwd)
$-0.35
ROE
-58.1%
ROA
-15.4%
Cash
$15.2M
Total Debt
$0
Free CF
-$4.3M
52W Change
-75.2%
Annual Financials
Cash vs Debt
Where MBIO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MBIO finished 42.19% below its 150-day moving average ($0.64) and 48.61% below its 200-day moving average ($0.72). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MBIO overbought or oversold?
At the October 20, 2026 close, MBIO's RSI(14) was 20.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Mustang Bio, Inc. reports $15.2M in cash and $0 in total debt. Free cash flow is running at -$4.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -58.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Mustang Bio, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing MBIO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.